RB1 deletion	Prostate Cancer	RB1 deletion	Prostate Cancer	abiraterone acetate Resistant: B - Late Trials abiraterone acetate Resistant : B	abiraterone acetate Resistant: B - Late Trials abiraterone acetate Resistant : B
RB1 deletion	Prostate Cancer	RB1 deletion	Prostate Cancer	enzalutamide Resistant: B - Late Trials enzalutamide Resistant : B	enzalutamide Resistant: B - Late Trials enzalutamide Resistant : B
RB1 overexpression	Breast Cancer	RB1 overexpression	Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
RB1 mutation	Urothelial Cancer	RB1 mutation	Urothelial Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
RB1 mutation + TP53 mutation	Urothelial Cancer	RB1 mutation + TP53 mutation	Urothelial Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
RB1 deletion	Hormone Receptor Positive Breast Cancer	RB1 deletion	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
RB1 mutation + PD-L1 expression	Bladder Cancer	RB1 mutation + PD-L1 expression	Bladder Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
RB1 mutation	Bladder Cancer	RB1 mutation	Bladder Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
RB1 expression	Glioblastoma	RB1 expression	Glioblastoma	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
RB1 mutation	Small Cell Lung Cancer	RB1 mutation	Small Cell Lung Cancer	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
RB1 expression	Liposarcoma	RB1 expression	Liposarcoma	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
RB1 expression	Soft Tissue Sarcoma	RB1 expression	Soft Tissue Sarcoma	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3

RB1 (RB Transcriptional Corepressor 1)

Associations(63)

Associations
(63)